Miyatake Satoko, Koshimizu Eriko, Fujita Atsushi, Fukai Ryoko, Imagawa Eri, Ohba Chihiro, Kuki Ichiro, Nukui Megumi, Araki Atsushi, Makita Yoshio, Ogata Tsutomu, Nakashima Mitsuko, Tsurusaki Yoshinori, Miyake Noriko, Saitsu Hirotomo, Matsumoto Naomichi
Department of Human Genetics, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Department of Pediatric Neurology, Pediatric Medical Care Center, Osaka City General Hospital, Osaka, Japan.
J Hum Genet. 2015 Apr;60(4):175-82. doi: 10.1038/jhg.2014.124. Epub 2015 Jan 22.
Whole-exome sequencing (WES) is becoming a standard tool for detecting nucleotide changes, and determining whether WES data can be used for the detection of copy-number variations (CNVs) is of interest. To date, several algorithms have been developed for such analyses, although verification is needed to establish if they fit well for the appropriate purpose, depending on the characteristics of each algorithm. Here, we performed WES CNV analysis using the eXome Hidden Markov Model (XHMM). We validated its performance using 27 rare CNVs previously identified by microarray as positive controls, finding that the detection rate was 59%, or higher (89%) with three or more targets. XHMM can be effectively used, especially for the detection of >200 kb CNVs. XHMM may be useful for deletion breakpoint detection. Next, we applied XHMM to genetically unsolved patients, demonstrating successful identification of pathogenic CNVs: 1.5-1.9-Mb deletions involving NSD1 in patients with unknown overgrowth syndrome leading to the diagnosis of Sotos syndrome, and 6.4-Mb duplication involving MECP2 in affected brothers with late-onset spasm and progressive cerebral/cerebellar atrophy confirming the clinical suspect of MECP2 duplication syndrome. The possibility of an 'exome-first' approach for clinical genetic investigation may be considered to save the cost of multiple investigations.
全外显子组测序(WES)正成为检测核苷酸变化的标准工具,确定WES数据是否可用于检测拷贝数变异(CNV)备受关注。迄今为止,已经开发了几种用于此类分析的算法,不过需要根据每种算法的特点进行验证,以确定它们是否适用于相应目的。在此,我们使用外显子隐马尔可夫模型(XHMM)进行了WES CNV分析。我们使用先前通过微阵列鉴定为阳性对照的27个罕见CNV验证了其性能,发现检测率为59%,或在有三个或更多靶点时更高(89%)。XHMM可有效用于检测大于200 kb的CNV,尤其适用于缺失断点检测。接下来,我们将XHMM应用于基因未明确诊断的患者,成功鉴定出致病性CNV:在患有不明过度生长综合征的患者中发现涉及NSD1的1.5 - 1.9 Mb缺失,从而诊断为索托斯综合征;在患有迟发性痉挛和进行性脑/小脑萎缩的患病兄弟中发现涉及MECP2的6.4 Mb重复,证实了MECP2重复综合征的临床怀疑。为节省多次检测的成本,可以考虑采用“外显子优先”的临床基因检测方法。